Publications by authors named "Anna Tinker"

Claim this Profile
B
Bridging historical evidence and contemporary strategies in the adjuvant treatment of early-stage epithelial ovarian cancer.
Madeline Rhind, Corinne Maurice-Dror, Yvette Drew, Lien Hoang, Anna V Tinker

Int J Gynecol Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Toxicities of Adolescent and Young Adults Who Underwent Radiation Therapy for Cervix Cancer: A Cross-Sectional Analysis.
Andrew G Pritchard, Melanie Altas, Anna V Tinker, Iwa Kong, Karen Goddard

J Adolesc Young Adult Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying high-risk relapse in early-stage I to II ovarian cancer using the CA125 ELIMination rate constant K (KELIM) score: a Gynecologic Cancer InterGroup individual patient-data meta-analysis.
Pauline Corbaux, Benoit You, Tatsuo Kagimura, Rosalind M Glasspool, Iain McNeish, Anna V Tinker

Int J Gynecol Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FOLR1 as a therapeutic target in platinum-resistant ovarian carcinoma: unique expression patterns across ovarian carcinoma histotypes and molecular subtypes of low-grade serous carcinoma.
Yuen Yee Leung, Marta Llaurado-Fernandez, Anna Cameron, Annalyn Da-Anoy, Linda C Cook, Anna V Tinker

J Gynecol Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Collaborative team-based care implementation in ambulatory gynecological and lung cancer clinics.
Shirin Abadi, Andrew Pool, Anna Tinker, Ying Wang, Andrea Crameri

J Oncol Pharm Pract· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in female cancer diagnostic billing rates over the COVID-19 period in the Ontario Health Insurance Plan.
Deanna McLeod, Ilidio Martins, Anna V Tinker, Amanda Selk, Christine Brezden-Masley

Ther Adv Med Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety.
Ursula A Matulonis, Jørn Herrstedt, Amit Oza, Sven Mahner, Andrés Redondo, Anna V Tinker

Gynecol Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer.
Whitney S Graybill, Ignace Vergote, Bhavana Pothuri, Maarit Anttila, David M O'Malley, Anna V Tinker

J Comp Eff Res· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial.
Abha A Gupta, Anna Tinker, Derek Jonker, Rahma Jamal, Hal Hirte

EClinicalMedicine· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes.
Lucy Haggstrom, Yeh Chen Lee, Clare Scott, Philipp Harter, Linn Woelber, Anna Tinker

Int J Gynecol Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Giorgio Valabrega, Bhavana Pothuri, Ana Oaknin, Whitney S Graybill, Ana Beatriz Sánchez, Anna V Tinker

Gynecol Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial.
Claire F Friedman, Anishka D'Souza, Diana Bello Roufai, Anna V Tinker, Maria de Miguel

Gynecol Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study.
Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, Renaud Sabatier, Jubilee Brown, Anna V Tinker

Clin Cancer Res· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial.
Thierry André, Dominique Berton, Giuseppe Curigliano, Renaud Sabatier, Anna V Tinker

JAMA Netw Open· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis.
Pauline Corbaux, Benoit You, Rosalind M Glasspool, Nozomu Yanaihara, Anna V Tinker

Eur J Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer.
Ana Oaknin, Lucy Gilbert, Anna V Tinker, Jubilee Brown, Cara Mathews

Future Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.
Todd M Bauer, Kathleen N Moore, Janet S Rader, Fiona Simpkins, Alain C Mita, Anna V Tinker

Target Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the childcare needs of cancer patients undergoing radiation therapy.
Zhang Hao Jim Li, Kenzie MacDonald, Katherine Preston, Meredith Giuliani, Bonnie Leung, Anna Tinker

Support Care Cancer· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD8 + T cell infiltration is associated with improved survival and negatively correlates with hypoxia in clear cell ovarian cancer.
Nancy Guo, Aijun Yang, Fabiha Binte Farooq, Shreena Kalaria, Elena Moss, Anna V Tinker

Sci Rep· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the adjuvant management and risk factors on survival in FIGO stage 3 endometrial cancer patients.
Nora Tong, Aalok Kumar, Gerald Gelowitz, Anna Tinker, Caroline Holloway

Front Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer.
Ana C Veneziani, Clare Scott, Matthew J Wakefield, Anna V Tinker, Stephanie Lheureux

Ther Adv Med Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer.
Anna V Tinker, Neesha C Dhani, Prafull Ghatage, Deanna McLeod, Vanessa Samouëlian

Ther Adv Med Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes" [Gynecologic Oncology, Volume 157, Issue 1, April 2020, Pages 36-45].
Stephanie A Scott, Marta Llaurado Fernandez, Hannah Kim, Laurie Elit, Melica Nourmoussavi, Anna V Tinker

Gynecol Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Germline Testing and Somatic Tumor Testing for Pathogenic Variants in Ovarian Cancer: What Is the Optimal Sequence of Testing?
Janice S Kwon, Anna V Tinker, Jennifer Santos, Katie Compton, Sophie Sun

JCO Precis Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cervical cancer patient reported gastrointestinal outcomes: intensity/volumetric modulated vs. 3D conformal radiation therapy.
Ryan Urban, Justin Wong, Peter Lim, Susan Zhang, Ingrid Spadinger, Anna V Tinker

J Gynecol Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis